Objective:To explore the clinical efficacy of Danshen injection in combined with local injection of triamcinolone acetonide in the treatment of oral submucous fibrosis (OSF) and the effect on serum TGF-β1 and IL-6.Me...Objective:To explore the clinical efficacy of Danshen injection in combined with local injection of triamcinolone acetonide in the treatment of oral submucous fibrosis (OSF) and the effect on serum TGF-β1 and IL-6.Methods:A total of 70 patients with OSF who were admitted in our hospital from October, 2015 to October, 2016 were included in the study and randomized into the observation group and the control group (n=35). The patients in the control group were given multipoint injection of triamcinolone acetonide (40 mg/time) in the basal region of oral mucosal regions. On this basis, the patients in the observation group were given additional Danshen injection (4 mL/time), 1 time/week, for 12 times. VAS was used for evaluation. The oral mucosa lesion area and mouth opening were measured. The morning fasting peripheral venous blood before and after treatment in the two groups was collected. The blood rheometer was used to detect the whole blood viscosity [high shear (HS), moderate shear (MS), and low shear (LS)], plasma viscosity (PV), and fibrinogen (FIB). ELISA was used to detect the serum TGF-β1 and IL-6 levels.Results: VAS score in the observation group was significantly reduced (P<0.05), mucosal lesion area was significantly less than that in the control group (P<0.05), and mouth opening was significantly greater than that in the control group (P<0.05). LS, MS, PV, and FIB after treatment in the observation group were significantly reduced when compared with before treatment (P<0.05), while LS, MS, HS, PV, and FIB after treatment in the control group were not significantly changed (P>0.05). TGF-β1 and IL-6 levels after treatment in the observation group were significantly lower than those in the control group (P<0.05).Conclusions: Danshen injection in combined with local injection of triamcinolone acetonide in the treatment of OSF can effectively reduce the serum TGF-β1 and IL-6 levels, inhibit the connective tissue fibrosis, and improve the pain, oral mucosal lesion area, and mouth opening, with a satisfactory clinical effect.展开更多
文摘Objective:To explore the clinical efficacy of Danshen injection in combined with local injection of triamcinolone acetonide in the treatment of oral submucous fibrosis (OSF) and the effect on serum TGF-β1 and IL-6.Methods:A total of 70 patients with OSF who were admitted in our hospital from October, 2015 to October, 2016 were included in the study and randomized into the observation group and the control group (n=35). The patients in the control group were given multipoint injection of triamcinolone acetonide (40 mg/time) in the basal region of oral mucosal regions. On this basis, the patients in the observation group were given additional Danshen injection (4 mL/time), 1 time/week, for 12 times. VAS was used for evaluation. The oral mucosa lesion area and mouth opening were measured. The morning fasting peripheral venous blood before and after treatment in the two groups was collected. The blood rheometer was used to detect the whole blood viscosity [high shear (HS), moderate shear (MS), and low shear (LS)], plasma viscosity (PV), and fibrinogen (FIB). ELISA was used to detect the serum TGF-β1 and IL-6 levels.Results: VAS score in the observation group was significantly reduced (P<0.05), mucosal lesion area was significantly less than that in the control group (P<0.05), and mouth opening was significantly greater than that in the control group (P<0.05). LS, MS, PV, and FIB after treatment in the observation group were significantly reduced when compared with before treatment (P<0.05), while LS, MS, HS, PV, and FIB after treatment in the control group were not significantly changed (P>0.05). TGF-β1 and IL-6 levels after treatment in the observation group were significantly lower than those in the control group (P<0.05).Conclusions: Danshen injection in combined with local injection of triamcinolone acetonide in the treatment of OSF can effectively reduce the serum TGF-β1 and IL-6 levels, inhibit the connective tissue fibrosis, and improve the pain, oral mucosal lesion area, and mouth opening, with a satisfactory clinical effect.
